利多卡因及其代谢物MEGX的人体药代动力学研究  

Studies on the Pharmacokinetics of Lidocaine and MEGX in Man

作　　者：林宇星[1] 施俊人[1] 

机构地区：[1]福建省立医院,福州350001

出　　处：《江苏药学与临床研究》2001年第2期3-5,共3页Jiangsu Pharmacertical and Clinical Research

摘　　要：测定了8名健康志愿者和4名肝硬化患者给药前及静脉注射利多卡因(1 mg/kg)后3,6,10,15,30,45,60,90,120,300 min利多卡因及其主要代谢物MEGX的血药浓度。通过对利多卡因和MEGX药动学模型的分析,发现肝硬化病人与正常人的MEGX药动学参数有显著差异。提示60 min时的MEGX血药浓度测定,不仅可作为一种简便、无创伤性的定量肝脏功能测试的手段,也适用于药物相互作用及个体化治疗药物监测的研究。We determined lidocaine and its primary metabolite monoethylglycinexylidide (MEGX) serum concentrations with the TDX (Abbott Laboratories) at baseline and 3,6 ,10,15,30,45, 60,90,120, 300 min after the intravenous administration of lidocaine (1 mg/kg), analyzing specimens from 8 apparently healthy volunteers and 4 patients with liver cirrhosis. A modelling analysis of lidocaine and MEGX kinetics was performed. The kinetics parameter of MEGX in cirrhosis group was significantly different from that in control group. The clinical MEGX test, based on a single determination 60 min after lidocaine injection, may be regarded as a simple, non-invasive and sensitive quantitative liver function test, and used in the investigation of drug interaction and individual therapeutic drug monitoring.

关 键 词：利多卡因 单乙基甘酰二甲苯胺 药代动力学 荧光偏振免疫分析 

分 类 号：R971.2[医药卫生—药品]